Zanubrutinib demonstrates prolonged progression-free survival in relapsed/refractory CLL/SLL, with a median PFS of 52.5 months and 49.9 months for patients with del17p. The ALPINE trial confirms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback